Source comparison
PT-141 Bioavailability: Route Comparison
Subcutaneous Injection >95% 30–60 minutes 1.75–2.0 mg Minimal (capillary absorption bypasses mucosal enzymes) Gold standard. Predictable dose-response, reproducible plasma curves, suitable for all research protocols requiring precise receptor occupancy Intrana
This comparison does not assign a generated winner or score.
- Subcutaneous Injection
- >95%
- 30–60 minutes
- 1.75–2.0 mg
- Minimal (capillary absorption bypasses mucosal enzymes)
- Gold standard. Predictable dose-response, reproducible plasma curves, suitable for all research protocols requiring precise receptor occupancy
- Intranasal Spray
- 2.6%
- 45–90 minutes
- 20–40 mg
- High (aminopeptidases and carboxypeptidases in nasal mucosa)
- Inconsistent. Absorption varies 40%+ between administrations, requires 10–20× dose to match subcutaneous exposure, not suitable for quantitative receptor studies
- Oral (tablet/capsule)
- <0.5%
- N/A (negligible absorption)
- Not viable
- Extreme (gastric acid + pepsin + intestinal proteases)
- Non-viable. Systemic exposure insufficient for melanocortin receptor activation, no published data supporting efficacy at any oral dose
- Sublingual (off-label)
- ~5–8% (estimated)
- 20–40 minutes
- 10–15 mg
- Moderate (salivary amylase + oral mucosa peptidases)
- Theoretical only. No published pharmacokinetic data for PT-141, likely better than oral but far worse than subcutaneous, absorption highly variable